Jim Cassidy

发表

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Prognostic factor analysis, for patients with no evidence of disease after initial chemotherapy for advanced epithelial ovarian carcinoma

W. Fullerton, A. Maclean, J. Davis, 1995, International Journal of Gynecologic Cancer.